Back to Stocks

XERS

Xeris Biopharma Holdings, Inc.
6 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Xeris Biopharma has reached a pivotal commercial inflection point, transitioning from a cash-burning biotech to a profitable specialty pharmaceutical entity.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the headline profitability, Xeris Biopharma remains burdened by a precarious balance sheet and significant looming liabilities.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every XERS filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing presents a company at a crossroads between successful commercial scaling and systemic financial risk. The shift to positive net income and operating cash flow is a critical milestone that validates the market demand for Recorlev and proves the company's ability to generate cash from its current portfolio. However, the magnitude of the company's debt relative to its quarterly earnings creates a narrow margin for error. Investors must weigh the impressive 95% growth of Recorlev against the legal threats from ANDA filers and the heavy interest burden of the 2029 loan. While the operational turnaround is evident, the ultimate trajectory of the stock will likely depend on the outcome of the patent litigation and the company's ability to either deleverage its balance sheet or successfully launch XP-8121 to diversify its revenue streams.

Selected Quarter

Core Takeaway

Xeris has proven its commercial model can generate profit, but it remains a high-leverage play with significant binary risk tied to patent litigation.

Investor Lens

The trade-off is between the current explosive growth of a single product and the systemic risk of its debt and legal vulnerabilities.

Watch Next

Court rulings on the four Hatch-Waxman patent lawsuits and progress toward Phase 3 for XP-8121.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.20Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 7

Achieved first positive net income of $2.2 million compared to a $9.2 million loss YoY.

earnings beat
90%
bullishMay 7

Cost of goods sold as a percent of revenue improved from 15.1% to 12.8%.

margin expansion
60%
bearishMay 7

Facing four major patent infringement lawsuits challenging Recorlev's exclusivity.

regulatory action
70%
neutralMay 7

Carries $221 million in debt with a significant maturity wall in 2029.

debt restructure
40%
bullishMay 7

Achieved first positive net income of $2.2 million compared to a $9.2 million loss YoY.

earnings beat
90%
bullishMay 7

Cost of goods sold as a percent of revenue improved from 15.1% to 12.8%.

margin expansion
60%
bearishMay 7

Facing four major patent infringement lawsuits challenging Recorlev's exclusivity.

regulatory action
70%
neutralMay 7

Carries $221 million in debt with a significant maturity wall in 2029.

debt restructure
40%
bullishMay 7

Achieved first positive net income of $2.2 million compared to a $9.2 million loss YoY.

earnings beat
90%
bullishMay 7

Cost of goods sold as a percent of revenue improved from 15.1% to 12.8%.

margin expansion
60%
bearishMay 7

Facing four major patent infringement lawsuits challenging Recorlev's exclusivity.

regulatory action
70%
neutralMay 7

Carries $221 million in debt with a significant maturity wall in 2029.

debt restructure
40%
bullishMay 7

Achieved first positive net income of $2.2 million compared to a $9.2 million loss YoY.

earnings beat
90%
bullishMay 7

Cost of goods sold as a percent of revenue improved from 15.1% to 12.8%.

margin expansion
60%
bearishMay 7

Facing four major patent infringement lawsuits challenging Recorlev's exclusivity.

regulatory action
70%
neutralMay 7

Carries $221 million in debt with a significant maturity wall in 2029.

debt restructure
40%
bullishMay 7

Achieved first positive net income of $2.2 million compared to a $9.2 million loss YoY.

earnings beat
90%
bullishMay 7

Cost of goods sold as a percent of revenue improved from 15.1% to 12.8%.

margin expansion
60%
bearishMay 7

Facing four major patent infringement lawsuits challenging Recorlev's exclusivity.

regulatory action
70%
neutralMay 7

Carries $221 million in debt with a significant maturity wall in 2029.

debt restructure
40%
bullishMay 7

Achieved first positive net income of $2.2 million compared to a $9.2 million loss YoY.

earnings beat
90%
bullishMay 7

Cost of goods sold as a percent of revenue improved from 15.1% to 12.8%.

margin expansion
60%
bearishMay 7

Facing four major patent infringement lawsuits challenging Recorlev's exclusivity.

regulatory action
70%
neutralMay 7

Carries $221 million in debt with a significant maturity wall in 2029.

debt restructure
40%

Filing History

10-QMay 7, 2026
Expand Sequence

The Q1 2026 filing presents a company at a crossroads between successful commercial scaling and systemic financial risk. The shift to positive net income and operating cash flow is a critical milestone that validates the market demand for Recorlev and proves the company's ability to generate cash from its current portfolio. However, the magnitude of the company's debt relative to its quarterly earnings creates a narrow margin for error. Investors must weigh the impressive 95% growth of Recorlev against the legal threats from ANDA filers and the heavy interest burden of the 2029 loan. While the operational turnaround is evident, the ultimate trajectory of the stock will likely depend on the outcome of the patent litigation and the company's ability to either deleverage its balance sheet or successfully launch XP-8121 to diversify its revenue streams.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.